Vertex Unveils New Data on ALYFTREK and CFTR Modulators at Cystic Fibrosis Conference
Reuters
Oct 23
Vertex Unveils New Data on ALYFTREK and CFTR Modulators at Cystic Fibrosis Conference
Vertex Pharmaceuticals Incorporated has announced the presentation of multiple new data sets across its cystic fibrosis $(CF)$ portfolio, including clinical results for its recently approved medicine, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), at the North American Cystic Fibrosis Conference (NACFC) held October 22-25 in Seattle, Washington. The presented abstracts include real-world and long-term outcomes for elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA), healthcare resource utilization over three years, and quality of life assessments among different age groups. Additional presentations cover clinical characteristics and outcomes among various genotypes, as well as unmet needs in populations not responsive to CFTR modulators. All results were presented during the NACFC conference.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertex Pharmaceuticals Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20251023956256) on October 23, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.